The Feasibility of the Connection between the Drug Patents Examination and the New Drug Registration
LI Hui1,2, SONG Xiao-ting1*
1. Shanghai International College of Intellectual Property, Tongji University, Shanghai 200092, China; 2. Department of Society Science, Zhejiang Chinese Medical University, Hangzhou 311402, China
Abstract��OBJECTIVE To improve the feasibility of the connection between the drug patents examination and the new drug registration and design the connecting pattern between them, which will enhance the appearance on the market for the patent drugs, eventually increase the drug choice for the public. METHODS To find the connecting space between drug patents examination and the evaluation standards for drug registration by comparing the ��novelty��, ��inventiveness��, ��practical applicability�� standards for a patent with the ��safety��, ��efficacy�� and ��quality�� standards for drug registration. RESULTS AND CONCLUSION A large connecting space between the practical applicability standard for a patent and the evaluation standards for drug registration is found in this paper. The practical applicability standard for a patent can be adjusted dynamically according to the evaluation standards for drug registration based on the development level of the pharmaceutical industry, interests of patent holders and the public, etc.
���,����ͤ. ҩƷר�����������ҩע�����˼·�Ŀ������о�[J]. �й�ҩѧ��־, 2017, 52(17): 1563-1568.
LI Hui, SONG Xiao-ting. The Feasibility of the Connection between the Drug Patents Examination and the New Drug Registration. Chinese Pharmaceutical Journal, 2017, 52(17): 1563-1568.
YUAN H M, YANG S J, SHANG L Y, et al. Idea and operation recommendations of patent linkage system in China[J]. Chin J Pharm(�й�ҽҩ��ҵ��־),2012,43(10):879-880.
[2]
YAO X F, ZHANG G C, DING J X. Feasibility study on the implementation of patent linkage system in China��based on analysis of stakeholders[J]. Chin J New Drugs(�й���ҩ��־),2016, 25(24):2814-2820.
[3]
ZHANG H, MA Q J, DENG S J. Sino-American patent challenges in generic drug industry[J]. Chin Pharm J(�й�ҩѧ��־),2016,51(16):1441-1442.
[4]
LIU J J, WU Z R. Expert investigation to establish drug patent linkage system in China[J]. Chin J New Drugs(�й���ҩ��־), 2016,25(11):1206.
[5]
WENG X Y. TRIPS and pharmaceutical patents[J]. Chin Pharm J(�й�ҩѧ��־), 2003,38(5):390.
[6]
CHEN H F. Research on the Intellectual Property Protection of Traditional Chinese Medicine Based on Economy(��ҩ֪ʶ��Ȩ�����ľ���ѧ�о�)[M]. Harbin: Harbin Institute of Technology Publishing House, 2016: 23.
[7]
State Intellectual Property Office of the People��s Republic of China. Guidebook to Patent Examination(ר�����ָ��)[M]. Beijing: Intellectual Property Publishing House, 2010: 170.
[8]
BAI H J. Comparison the rights and interests between the patent certificate and the new drug certificate[J]. Chin New Drugs J(�й���ҩ��־), 2000,9(2):135.
[9]
YANG D Q. Research on the judgment standard of utility of patent in the US patent law[J]. Intellect Property(֪ʶ��Ȩ),2015,(5):94.
[10]
State Intellectual Property Office of the People��s Republic of China. Guidebook to Patent Examination(ר�����ָ��)[M]. Beijing: Intellect Property Publishing House, 2010: 186.
[11]
YANG D Q. Research on the judgment standard of utility of patent in the US patent law[J]. Intel Property(֪ʶ��Ȩ),2015,(5):98.
[12]
CUI G B. Patent Law: Cases and Materials(ר����ԭ���밸��)[M]. 2nd ed. Beijing: Beijing University Publishing House, 2016:185.
[13]
WANG Z G, HE Y L, TIAN K. Rethink on censorship of patent of TCM industry in view of patent conversion[J]. Chin Health Service Manag(�й�������ҵ����),2014,31(12):924-928.
[14]
CHEN Y. The exploration and enlightenment about the utility of patent in USA[J]. Tech Manag Res(��������������о�),2014,(11):39-42.
[15]
GENG S Y, GENG L D, OUYANG X Y. Status analysis and countermeasure research for patent application quality of traditional Chinese medicine [J]. Chin J Inf Tradit Chin Med(�й���ҽҩ��Ϣ��־),2016,23(1):18-22.
[16]
CHEN Y F. Research on the compatibility of the traditional Chinese medicine and patent system based on the view of examination standards for practical applicability for traditional Chinese medicine[J]. Theory Reform(������ĸ�),2016,(2):122-127.
[17]
JIANG C. The original innovation ability of new drug research and development in our country is still insufficient [N]. China Pharmaceuticals Newspaper(�й�ҽҩ��),20160628(006).
2017, Vol. 52 
